What Avalon Pharma does

Avalon Pharma is a Saudi Arabian pharmaceutical manufacturer founded in 1998 and headquartered in Riyadh, publicly listed on the Saudi Exchange (Tadawul) under ticker 4016. The company develops and manufactures branded pharmaceutical-based health and beauty products, with a stated emphasis on eco-friendly formulations and sustainable product development dating to its founding. Its product portfolio spans prescription medicines and consumer health/beauty offerings built on scientifically researched formulations with clinically-proven ingredients. The company is led by Chairman Ahmad Tabbaa and President & CEO Maher Ghannam. Avalon distributes through traditional pharmaceutical wholesale channels serving pharmacies and healthcare providers in Saudi Arabia and the wider MENA region, operating a sales-led go-to-market model targeting both healthcare consumers and patients.

Avalon reported revenue of SAR 130 million with 34% year-over-year growth and net profit of SAR 27 million with 39% growth, implying a net margin of approximately 21%. The business is financed in part through Shariah-compliant debt — SAR 70 million from Emirates NBD in July 2024 and approximately SAR 54 million from The Saudi Investment Bank in August 2025 — supporting operational expansion. In February 2026, Avalon entered a strategically significant licensing and commercialization agreement with Chinese biotech Bio-Thera Solutions for BAT3306, a proposed pembrolizumab (Keytruda) biosimilar, covering Saudi Arabia and the broader MENA region; Bio-Thera retains development, manufacturing, and supply responsibility while Avalon leads commercialization in licensed territories. This deal represents a material move into specialty oncology biosimilars beyond its traditional generic and consumer health portfolio.

Avalon has earned external recognition including Great Place to Work certification in 2025 and 2026, and an Argaam Best CEO award for 2025, alongside CSR engagements such as a World No Tobacco Day awareness initiative with NAQA Association. The company's competitive positioning rests on regulatory-licensed manufacturing, an established regional distribution footprint, brand heritage built since 1998, and an eco-friendly differentiation narrative — though evidence of substantive AI/ML or proprietary technology depth is limited.

Name

Avalon Pharma

Legal name

Avalon Pharma

Website

https://avalonpharmaceutical.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

251–500 employees

Short description

Avalon Pharma is a Riyadh-headquartered, publicly listed Saudi pharmaceutical manufacturer founded in 1998, producing branded prescription medicines and consumer health/beauty products for distribution through wholesale channels across Saudi Arabia and the broader MENA region.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Health beauty products
• Prescription drugs
• Biosimilar distribution

Headquarters

HQ city

Riyadh

HQ country

Saudi Arabia

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Avalon Pharma generates revenue through the manufacture and sale of pharmaceutical products and health and beauty products. The company develops branded products rooted in scientific research with clinically-proven ingredients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Avalon Pharma manufactures and distributes branded pharmaceutical-based health and beauty products as well as generic prescription medicines, developed through scientific research with clinically-proven ingredients and a commitment to eco-friendly, sustainable formulations. The portfolio is rooted in rigorous testing and trials to ensure quality, and the company is expanding its therapeutic footprint through biosimilar licensing partnerships such as the Bio-Thera Solutions BAT3306 (pembrolizumab biosimilar) deal covering Saudi Arabia and the MENA region.

Product overview

Avalon Pharma offers a portfolio of pharmaceutical-based health and beauty products. The company operates across multiple segments including product development, manufacturing, and business development. Their product range includes both pharmaceutical treatments and consumer health/beauty offerings, though specific product brand names are not detailed in the available source data. The company also recently entered into a commercialization and license agreement with Bio-Thera Solutions for BAT3306, a proposed biosimilar to Keytruda (pembrolizumab), covering Saudi Arabia and the wider MENA region.

Differentiator

Problem solved

Functional benefit

Products and services

• Avalon Pharma branded health and beauty products A portfolio of pharmaceutical-based health and beauty brands developed with scientifically researched, clinically-proven ingredients and eco-friendly formulations, designed to address health conditions, wellness needs, and beauty concerns for end consumers.
• Avalon Pharma generic prescription medicines Generic prescription pharmaceutical products manufactured by Avalon Pharma, distributed through wholesale and pharmacy channels in Saudi Arabia and the MENA region to provide effective pharmacological treatments.
• BAT3306 (pembrolizumab biosimilar) A proposed biosimilar to Keytruda (pembrolizumab) that Avalon Pharma will commercialize under a license from Bio-Thera Solutions across Saudi Arabia and the wider MENA region for oncology indications.

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Bio-Thera SolutionscoreStrategic or Co-development Partner · 9 February 2026Chinese biotech Bio-Thera Solutions signed commercialization and license agreements with Avalon Pharma for BAT3306, a proposed biosimilar to Keytruda (pembrolizumab), covering Saudi Arabia and the wider Middle East and North Africa region. Bio-Thera retains responsibility for development, manufacturing, and supply while Avalon pursues regulatory approvals and leads commercialization across licensed territories.
• NAQA AssociationOthersAvalon Pharma partnered with NAQA Association to launch an awareness initiative on World No Tobacco Day, demonstrating corporate social responsibility engagement.

Scale indicators4 records

Recent moves3 records

Expansion highlights4 records

Direct peers

• Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO): Saudi Arabia's largest listed pharmaceutical manufacturer producing branded generics and OTC products — directly comparable to Avalon in therapeutic focus, manufacturing footprint, and Tadawul listing.
• Tabuk Pharmaceuticals: Leading Saudi generic pharma manufacturer with MENA presence — closely comparable product portfolio (branded generics, OTC, health & beauty adjacencies) and target customers (pharmacies and healthcare providers).
• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered generic and specialty pharma manufacturer with regional MENA distribution — directly comparable as a regional pharma manufacturer operating across the same geographies and therapeutic categories.
• Pharmax Pharmaceuticals: UAE-based generic and specialty pharma manufacturer with regional MENA distribution — directly comparable branded generics business model and geographic customer footprint.
• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest generic pharma manufacturers in the MENA region — directly comparable as a regional generics manufacturer serving similar healthcare provider and pharmacy channels.

Broad incumbents

• Hikma Pharmaceuticals: Jordan-anchored multinational generics and specialty pharma with deep MENA presence — broader portfolio and global scale but directly overlapping product categories and regional customer base as Avalon.
• Cipla: Global generics major with active presence in MENA through partnerships — broader scale and geographic reach but overlapping generic pharma product category and emerging-market commercialization model.

Emerging players

• Bio-Thera Solutions: China-based biosimilar developer and Avalon's commercialization partner for BAT3306 (Keytruda biosimilar) — comparable as a biosimilar-focused biotech targeting emerging markets, with overlapping oncology pipeline intent.

Regional players

• Al-Takween (National Medical Products Co.): Saudi pharma manufacturer focused on health, beauty, and personal care pharmaceutical products — comparable in the consumer health and beauty segment Avalon also targets.
• Middle East Pharmaceutical Industries Co. (Avalon Pharma referenced shareholder notice): Saudi-domiciled pharmaceutical manufacturer referenced alongside Avalon in shareholder communications — regional peer with overlapping manufacturing and distribution profile in Saudi Arabia.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Avalon_Pharma
• Facebookfacebook.com/avalonpharmaceutical
• LinkedInlinkedin.com/company/avalon-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avalon Pharma